Antibiotic Development

 

 

This track covers everything from discovery through to commercialization and payment reform. Learn about the latest innovative pre-clinical, clinical, commercial pathways, and best practices in traditional and nontraditional antibiotic development. Dive into conversations on “pull” incentives with industry leaders, heads of commercial development and policymakers.

 

Antibiotic R&D, Thursday 7 November 2019

Conference Registration

Concrete Commercial Initiatives

Jonathan Van-Tam
08:40

Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

09:20

Sponsored keynote address

TITLE SPONSOR SLOT
10:20

SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK

Early Development

John Prendergast
Antibiotic R&D
11:15

How synthetic antibiotic development can change the antibiotic treatment model

Mark Albrecht
Antibiotic R&D
11:35

How BARDA Incentivizes antibacterial development from early development through marketing approval

Saransh Chaudhary
Antibiotic R&D
11:55

Oral Ceftriaxone - a proof-of-concept for a novel drug delivery platform

Sheila Connelly
Antibiotic R&D
12:15

How degrading residual antibiotics in the GI tract may prevent the emergence of anti-microbial resistance in the gut microbiome

12:35

Networking Lunch Break

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Christine Årdal
14:10

Roundtable 10 Market Access - overcoming access barriers for smaller markets - considerations for countries and developers

Christian Lillis
14:10

Roundtable 11 Patient Advocacy - what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiativ

Marco Taglietti
14:10

Roundtable 12 Candida auris - a ticking time bomb: responding to an urgent global public health threat

Dave Ousterout
14:10

Roundtable 13 Phage development - Opportunities in development of novel phage therapies

Debbie Goff
14:10

Roundtable 14 Global collaboration – global stakeholder collaboration between clinicians, policy makers, pharmaceutical/diagnostic companies is needed to succeed at ASP

Amy Kirby
14:10

Roundtable 15 Water Quality – understanding transmission of waterborne pathogens and how the international community can combat the spread of resistance through integrating advanced lab techniques

Jeffrey Cies
14:10

Roundtable 16 Drug dosing – anti-infective underdosing and opportunities for customized drug dosing

Kartik Cherabuddi
14:10

Roundtable 2 Controlling c.dif - determining who to test and how to prevent additional outbreaks in the hospital

Richard Vickers
14:10

Roundtable 3 Innovation & stewardship - Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship.

Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes.
Justine Ross
14:10

Roundtable 4 Customizing Epic – the use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center

Colm Leonard
14:10

Roundtable 5 Antimicrobial value assessment - a look into the role of HTA in the UK's testing of novel assessment and delinked payment program

Jay K Varma
14:10

Roundtable 6 Policy in Africa- advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans

Brian Tse
14:10

Roundtable 7 Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Ryan Devies
14:10

Roundtable 8 Advancing Preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs

Jane Knisely
14:10

Roundtable 9 Supporting development - NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening

NIH programs filling the gaps in traditional and non-traditionaltherapeutic discovery & development with grants, contracts,in-vitro and in vivo screening and manufacturing capabilities and more.

Trial Design

Cara Cassino
Antibiotic R&D
15:15

Novel Trial Designs for non-traditional anti-infectives – Lessons learned from the Exebacase superiority design trial

Michael P Bevilacqua
Antibiotic R&D
15:35

Working with regulators to advance non-traditional therapies to prevent and treat life-threatening infections in surgery and trauma

16:35

Networking coffee break

Supported by BD

18:15

Drinks Reception

Thomas Cueni
18:15

Welcoming remarks by AMR Industry Alliance

Cocktail Reception hosted by AMR Industry Alliance
last published: 11/Oct/19 22:05

Antibiotic R&D, Friday 8 November 2019

08:00

Conference Registration

Tom Lowery
09:25

Keynote Address: The impact of rapid, direct-from-blood diagnostics in enabling changes in clinical decisions and improving outcomes

10:30

Networking coffee break

Commercial & Partnerships

Jenny Hellman
Antibiotic R&D
11:15

Pilot reimbursement models to ensure access of new antibiotics in Sweden - Collaboration between industry and government agencies to ensure a model that works for all stakeholders

Monika Schneider
Antibiotic R&D
11:35

Short and long-term payment strategies for a sustainable market – impact of NTAP modifications, DRG carve-out, and potential subscription models

12:35

Networking Lunch Break

13:40

Networking Lunch Break Resumes

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Clifford Mcdonald
14:10

Roundtable 10 Microbiome & CDC – Discussing a vision for precision public health novel approaches to treating infection prevention through the microbiome

Minh-Hong Nguyen
14:10

Roundtable 11 Developing diagnostics – novel approaches to development

Minh-Hong Nguyen, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, University of Pittsburgh
Courtney Jones
14:10

Roundtable 12 Infection intervention – using the microbiome to make antibiotics effective again

Mary Millard
14:10

Roundtable 13 Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Wes Kim
14:10

Roundtable 14 SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Jomana Musmar
14:10

Roundtable 15 One Health - The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) recommending federal One Health action to address AMR

Sarah De Clercq
14:10

Roundtable 16 AMR in Belgium – Creating a one health National Action Plan on AMR – rollout and next steps

Sumathi Nambiar
14:10

Roundtable 17 FDA Roundtable discussion

Nick Van Hise
14:10

Roundtable 2 The fecal microbiome - new approaches to the treatment of C. difficile infection

Eugean Jiwanmall
14:10

Roundtable 3 Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensus

Thomas Heymann
14:10

Roundtable 4 AMR and Sepsis - we are all in this together

Eili Klein
14:10

Roundtable 5 Surveillance

Examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR.
Angella Browne
14:10

Roundtable 7 Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Jeanette Mucha
14:10

Roundtable 8 CARB-X Accelerator – Company perspective on CARB-X Accelerator - What worked and what can be improved?

Abigail Colson
14:10

Roundtable 9 Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Wes Kim
14:10

Roundtable: SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Business Models & Partnership

Antibiotic R&D
15:15

SILVER SPONSOR SESSION

If you are interested in sponsoring this session in the Antibiotic R&D Track, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com.
Zak Zimmerman
Antibiotic R&D
15:35

Innovative business partnerships to build a portfolio of novel antibiotics

Terry Roemer
Antibiotic R&D
15:55

Rationale for in-licensing early stage antibacterial assets

last published: 11/Oct/19 22:05

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates